公开(公告)号：US10054599B2

公开(公告)日：2018-08-21

申请号：US14773677

申请日：2014-03-12

Applicant: Agency for Science, Technology and Research (A*STAR) ,  Singapore Health Service PTE LTD

Inventor： Sai Kiang Lim ,  Kok Hian Tan

IPC: G01N33/68 ,  A61K31/166 ,  A61K31/4422 ,  A61K31/4439 ,  A61K31/502 ,  A61K33/06

CPC classification number: G01N33/689 ,  A61K31/166 ,  A61K31/4422 ,  A61K31/4439 ,  A61K31/502 ,  A61K33/06 ,  G01N33/6893 ,  G01N2333/4727 ,  G01N2333/495 ,  G01N2333/5412 ,  G01N2333/58 ,  G01N2333/585 ,  G01N2333/70596 ,  G01N2333/71 ,  G01N2333/8132 ,  G01N2333/8146 ,  G01N2333/9129 ,  G01N2570/00 ,  G01N2800/368 ,  G01N2800/52 ,  G01N2800/60 ,  Y02A50/471

Abstract: We describe a method of detecting pre-eclampsia in a cell, tissue, organ or organism, the method comprising detecting a modulated level of expression, activity or amount of a pre-eclampsia biomarker polypeptide selected from the group consisting of PlGF, FLT1, BNP, ANP, CD9, PAI-1, TGF β, PCT, SI 00b, TIMP1, CD 105 and IL6 in or of a microparticle type (selected from a CTB binding microparticle and an Annexin V binding microparticle) from the cell, tissue, organ or organism, as compared to level of expression, activity or amount of the pre-eclampsia biomarker polypeptide in the same microparticle type in a cell, tissue, organ or organism not sufferin from pre-eclampsia.

公开(公告)号：US20170370947A1

公开(公告)日：2017-12-28

申请号：US15675367

申请日：2017-08-11

Applicant: Rules-Based Medicine, Inc.

Inventor： Samuel T. LaBrie ,  James P. Mapes ,  Ralph L. McDade ,  Dominic Eisinger ,  Karri L. Ballard

IPC: G01N33/68 ,  G01N33/566 ,  G01N33/53

CPC classification number: G01N33/6893 ,  G01N33/5302 ,  G01N33/566 ,  G01N2333/47 ,  G01N2333/4703 ,  G01N2333/4706 ,  G01N2333/4725 ,  G01N2333/4727 ,  G01N2333/475 ,  G01N2333/52 ,  G01N2333/70503 ,  G01N2333/70539 ,  G01N2333/765 ,  G01N2333/775 ,  G01N2333/8139 ,  G01N2333/8146 ,  G01N2333/82 ,  G01N2333/91177 ,  G01N2800/34 ,  G01N2800/347 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/60 ,  Y10T436/147777

Abstract: Methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

公开(公告)号：US20170307634A1

公开(公告)日：2017-10-26

申请号：US15641203

申请日：2017-07-03

Applicant: ASTUTE MEDICAL, INC.

Inventor： Joseph Anderberg ,  Jeff Gray ,  Paul McPherson ,  Kevin Nakamura ,  James Patrick Kampf

IPC: G01N33/68 ,  G01N33/70 ,  G06F19/00 ,  G06F19/24

CPC classification number: G01N33/6893 ,  G01N33/70 ,  G01N2333/4703 ,  G01N2333/4745 ,  G01N2333/65 ,  G01N2333/8146 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/56 ,  G16B40/00 ,  G16H50/20 ,  Y02A90/26

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a measured urine concentration of one or more of TIMP2 and IGFBP7 in combination with one or more of a measured serum creatinine and a measured urine output, which results are correlated to the renal status of the subject, and can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure.

公开(公告)号：US20170115294A1

公开(公告)日：2017-04-27

申请号：US15399801

申请日：2017-01-06

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Norbert Wild ,  Ursula Garczarek ,  Andrea Geistanger ,  Herbert Andres ,  Marie-Luise Hagmann ,  Johann Karl ,  Freidemann Krause ,  Michael Pfeffer ,  Wolfgang Rollinger ,  Michael Tacke ,  Michael Thierolf

IPC: G01N33/574

CPC classification number: G01N33/57419 ,  C12Q1/6886 ,  G01N2333/4727 ,  G01N2333/805 ,  G01N2333/8146 ,  G01N2333/9121

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.

公开(公告)号：US20170023590A1

公开(公告)日：2017-01-26

申请号：US15287162

申请日：2016-10-06

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： Susan Faas MCKNIGHT ,  Roxanne COFIELL ,  Anjli KUKREJA ,  Krystin A. BEDARD ,  Yan YAN

IPC: G01N33/68 ,  C07K16/18

CPC classification number: G01N33/6893 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/76 ,  G01N33/6863 ,  G01N2333/4716 ,  G01N2333/485 ,  G01N2333/522 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/5434 ,  G01N2333/545 ,  G01N2333/57 ,  G01N2333/70503 ,  G01N2333/70525 ,  G01N2333/70539 ,  G01N2333/7151 ,  G01N2333/7452 ,  G01N2333/75 ,  G01N2333/775 ,  G01N2333/8139 ,  G01N2333/8146 ,  G01N2333/974 ,  G01N2800/226 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/52

Abstract: The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.

Abstract translation: 本公开提供了生物标志物蛋白质，其浓度或活性水平的变化与非典型溶血性尿毒症综合征（aHUS）相关，或临床意义上用补体抑制剂治疗HUS。 还提供了用于询问生物流体中一种或多种生物标记蛋白的浓度和/或活性的组合物和方法。 组合物和方法可用于评估发展为高血压的风险，诊断高血压，确定受试者是否正在经历第一次急性呈现的HUS，监测进展或减轻HUS，和/或监测对治疗的反应 补体抑制剂或优化这种治疗。

公开(公告)号：US20160216267A1

公开(公告)日：2016-07-28

申请号：US14915395

申请日：2014-07-22

Applicant: Raybiotech, Inc. Guangzhou ,  South China Biochip Research Center in Guangzhou

Inventor： Ruopan Huang ,  Weidong Jiang ,  Ruochun Huang

IPC: G01N33/574

CPC classification number: G01N33/57449 ,  G01N33/57484 ,  G01N2333/4706 ,  G01N2333/4725 ,  G01N2333/70578 ,  G01N2333/71 ,  G01N2333/8146 ,  G01N2800/60

Abstract: Disclosed are antibody arrays for the detection of cancer in a human or animal subject, comprising a solid support having disposed thereon in a predetermined spatial configuration, a panel of antibodies specific to biomarkers comprising CA-125, MSP-α, TIMP-4, PDGF-Rα and OPG, wherein the panel comprises a first antibody or fragment thereof that specifically binds CA-125, a second antibody or fragment thereof that specifically binds MSP-α, a third antibody or fragment thereof that specifically binds TIMP-4, a fourth antibody or fragment thereof that specifically binds PDGF-Rα, and a fifth antibody or fragment thereof that specifically binds OPG. Also disclosed are systems containing the arrays and methods of using the arrays to detect cancer such as ovarian cancer.

Abstract translation: 公开了用于在人或动物对象中检测癌症的抗体阵列，其包含以预定空间构型设置在其上的固体支持物，对于包含CA-125，MSP-α，TIMP-4，PDGF的生物标志物特异的一组抗体 -Rα和OPG，其中所述面板包含特异性结合CA-125的第一抗体或其片段，特异性结合MSP-α的第二抗体或其片段，特异性结合TIMP-4的第三抗体或其片段，第四抗体 特异性结合PDGF-Rα的抗体或其片段，以及特异性结合OPG的第五抗体或其片段。 还公开了包含阵列的系统和使用阵列来检测诸如卵巢癌的癌症的方法。

公开(公告)号：US20160154009A1

公开(公告)日：2016-06-02

申请号：US15013833

申请日：2016-02-02

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： Susan Faas MCKNIGHT ,  Roxanne COFIELL ,  Anjli KUKREJA ,  Krystin A. BEDARD ,  Yan YAN

IPC: G01N33/68 ,  C07K16/18

CPC classification number: G01N33/6893 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/76 ,  G01N33/6863 ,  G01N2333/4716 ,  G01N2333/485 ,  G01N2333/522 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/5434 ,  G01N2333/545 ,  G01N2333/57 ,  G01N2333/70503 ,  G01N2333/70525 ,  G01N2333/70539 ,  G01N2333/7151 ,  G01N2333/7452 ,  G01N2333/75 ,  G01N2333/775 ,  G01N2333/8139 ,  G01N2333/8146 ,  G01N2333/974 ,  G01N2800/226 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/52

Abstract: The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.

Abstract translation: 本公开提供了生物标志物蛋白质，其浓度或活性水平的变化与非典型溶血性尿毒症综合征（aHUS）相关，或临床意义上用补体抑制剂治疗HUS。 还提供了用于询问生物流体中一种或多种生物标记蛋白的浓度和/或活性的组合物和方法。 组合物和方法可用于评估发展为高血压的风险，诊断高血压，确定受试者是否正在经历第一次急性呈现的HUS，监测进展或减轻HUS，和/或监测对治疗的反应 补体抑制剂或优化这种治疗。

公开(公告)号：US20150355196A1

公开(公告)日：2015-12-10

申请号：US14761591

申请日：2014-01-16

Applicant: ASTUTE MEDICAL, INC.

Inventor： Joseph Anderberg ,  Jeff Gray ,  Paul McPherson ,  Kevin Nakamura ,  James Patrick Kampf

IPC: G01N33/68 ,  G06F19/24 ,  G06F19/00 ,  G01N33/70

CPC classification number: G01N33/6893 ,  G01N33/70 ,  G01N2333/4703 ,  G01N2333/4745 ,  G01N2333/65 ,  G01N2333/8146 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/56 ,  G06F19/00 ,  G06F19/24 ,  G16H50/20 ,  Y02A90/26

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a measured urine concentration of one or more of TIMP2 and IGFBP7 in combination with one or more of a measured serum creatinine and a measured urine output, which results are correlated to the renal status of the subject, and can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure.

Abstract translation: 本发明涉及用于在患有或疑似患有肾损伤的受试者中监测，诊断，预后和确定治疗方案的方法和组合物。 特别地，本发明涉及使用TIMP2和IGFBP7中的一种或多种的测量尿液浓度与测量的血清肌酐和测量的尿液输出中的一种或多种组合，其结果与受试者的肾脏状态相关，以及 可用于患有或患有肾功能损伤，肾功能减退和/或急性肾功能衰竭的受试者的诊断，预后，风险分层，分期，监测，分类和确定进一步的诊断和治疗方案。

公开(公告)号：US20130045494A1

公开(公告)日：2013-02-21

申请号：US13395114

申请日：2010-09-17

Applicant: Joseph Anderberg ,  Jeff Gray ,  Paul McPherson ,  Kevin Nakamura ,  James Patrick Kampf

Inventor： Joseph Anderberg ,  Jeff Gray ,  Paul McPherson ,  Kevin Nakamura ,  James Patrick Kampf

IPC: G01N21/78

CPC classification number: G01N33/6893 ,  G01N33/6854 ,  G01N2333/7452 ,  G01N2333/8146 ,  G01N2800/347 ,  G01N2800/56

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Immumoglobulin A, Metalloproteinase inhibitor 4, and Thrombomodulin as diagnostic and prognostic biomarker assays in renal injuries.

Abstract translation: 本发明涉及用于在患有或疑似患有肾损伤的受试者中监测，诊断，预后和确定治疗方案的方法和组合物。 特别地，本发明涉及使用检测一种或多种选自下组的生物标志物的测定法，其中所述生物标志物选自由下列组成的组：免疫球蛋白A，金属蛋白酶抑制剂4和血栓调节蛋白，作为肾损伤中的诊断和预后生物标志物测定。

公开(公告)号：US20120010094A1

公开(公告)日：2012-01-12

申请号：US13128200

申请日：2009-11-04

Applicant: Francis G. Spinale ,  Michael R. Zile ,  Robert E. Stroud

Inventor： Francis G. Spinale ,  Michael R. Zile ,  Robert E. Stroud

IPC: C40B30/04 ,  G01N33/566 ,  G01N33/573 ,  C12Q1/37

CPC classification number: G01N33/6893 ,  G01N2333/4703 ,  G01N2333/52 ,  G01N2333/58 ,  G01N2333/78 ,  G01N2333/8146 ,  G01N2800/325 ,  G01N2800/60

Abstract: Disclosed herein are methods of detecting, monitoring, and predicting left ventricular hypertrophy, congestive heart failure and related conditions by profiling biomarkers.

Abstract translation: 本文公开了通过分析生物标志物检测，监测和预测左心室肥大，充血性心力衰竭和相关病症的方法。